Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Cancer Immunol Res. 2023 Sep 1;11(9):1222–1236. doi: 10.1158/2326-6066.CIR-22-0254

Figure 2: AXL inhibition with TP-0903 selectively reduces Th2 cells and cytokines and enhances CART19-cell proliferation.

Figure 2:

A, Naïve T cells were stimulated with 50 ng/mL of PMA and 1 µg/mL of ionomycin for 4 hours in the presence of increasing doses of TP-0903 (10–30 nM). Flow cytometric analysis was used to assess activation of T cells by CD107a degranulation and intracytoplasmic cytokine production (IL2, IFNγ, IL4, IL13). n=3 biological replicates. B, Naïve T cells were stimulated with 5 ng/mL of PMA and 0.1 µg/mL of ionomycin for 3 days in the presence of TP-0903 (30 nM). Flow cytometric analysis was used to evaluate CD4+CXCR3+CCR4+ T cells (** p<0.01, t-test, n=3 biological replicates). C, CART19 cells were co-cultured with the CD19+ mantle cell lymphoma cell line JeKo-1 in the absence or in the presence of TP-0903 (10 nM) for 5 days. CART19 cell proliferation was then assessed for total, CD8+, and CD4+ T cells. n=3 biological replicates. D, CART19 cells were co-cultured with JeKo-1 in the presence of TP-0903 (10 nM) for 5 days and chemokine receptors were stained. Th1, Th2, and the CD4+CXCR3+CCR4+ fractions were assessed. ** p<0.005, t-test, n=3 biological replicates. E, CART19 cells were co-cultured with JeKo-1 cells for 3 days with/without TP-0903, and supernatants were analyzed for human cytokines and chemokines (38-multiplex). * p<0.05, ** p<0.01, *** p<0.001, n=2 biological replicates. Data are plotted as means ± SEM.